Paris, December 17th, 2020 – Chronolife, a French artificial intelligence company specializing in digital health, announced today that…
Chronolife, recently ISO 13 485 certified, receives CE mark approval for its Smart Textile solution and announces a strategic partnership
Paris, France, 03 July 2019 – Chronolife, an artificial intelligence company specialized in digital health with a patented edge computing technology and algorithm named HOTS, receives CE (Conformité Européenne) marking in addition to FCC (Federal Communications Commission) certification for its Smart Textile monitoring solution. Chronolife has also announced that it will collaborate with BePatient, specialized in e-health solutions.
The Smart Textile solution developed by Chronolife includes a comfortable multi-sensory T-shirt that collects, stores, and transmits data on six physiological indicators:
• Abdominal breathing
• Thoracic breathing
• Body temperature
• Physical actvity
• Pulmonary impedance
The data collected is transmitted to a smartphone application via a BTLE (BlueTooth Low Energy) link before being transmitted to secure, certified servers. All the data is then made available on a web portal for more in-depth analysis.
Smart Textile solution is intended to be used in situations requiring large amounts of continuous data onmultiple physiological parameters. Some examples include using in risk reduction programs for return to work/stay at work initiatives after sick leave or injury by corporations or insurance
companies, accompanying programs for ageing in place, as well as athletes’ rehabilitation programs after an injury.
“Presently there is an increasing demand in the healthcare market to have reliable and long term monitoring solutions that are easy to adopt and deploy to detect complications after injury or illness and anticipate interventions. The CE mark on Smart Textile TM is a very important milestone for Chronolife and we will immediately initiate its launch in Europe followed by US” says Laurent Vandebrouck, company’s CEO. Chronolife also seeks to obtain CE marking class IIa for use as a medical device.
Smart Textile is unique in its ability to provide continuous data recording and ease of wear as it is worn and washed like a regular shirt without removing any electronic components.
In order to be able to deploy and operate end-to-end services for prevention, risk reduction and remote patient monitoring using its connected washable T-shirt, Chronolife has started signing partnership agreements with web portal operators and service providers specialised in programs for prevention, risk management and ageing in place. Chronolife and BePatient have teamed up to develop and deploy such offers targeting the healthcare industries in France.
BePatient is a web platform dedicated to prevention and support to people suffering of chronic illnesses as well as to their health care professionals. The start-up offers innovative technological solutions, as well as personalized services to support users in improving their quality of life, preventing potential complications and gaining greater independence in their health care.
By combining the power of Chronolife’s connected multiparametric t-shirt with BePatient’sinnovative solution, the duo can take connected health to the next level. Uniting their strengths the two companies want to offer an improved continuum of care for people with chronic conditions through
Co-founded with IBionext, Chronolife is an artificial intelligence company specialized in digital health. Its patented technology is a unique neuromorphic algorithm called HOTS (Hierarchy Of event-based
Time Surfaces), which analyses several data flows continuously, to characterize clinical events. Chronolife has developed a smart wearable that integrates various sensors to monitor physiological data continuously. This data is analyzed by the smartphone application on a patient’s phone that uses HOTS technology to conduct data fusion. It is capable of detecting changes in a patient’s health and triggering alerts to healthcare professionals to predict acute pathological episodes. IBionext Growth Fund has invested in the startup and is the reference shareholder since Chronolife’s creation.
firstname.lastname@example.org – +33 (0)1 47 59 56 39